QP 21 - Heme 4:The Power Duo: CAR T Cells and Radiotherapy in Tandem

Moderator(s)

• 

  Jennifer Peterson, MD

  Mayo Clinic College of Medicine and Science Jacksonville
  Jacksonville, FL
• 

  Brandon Imber, MD, MS

  Memorial Sloan Kettering Cancer Center
  New York, NY

Presentations:

• 8:00 AM – 8:05 AM ET

  Introduction
• 8:05 AM – 8:10 AM ET

  Normalization of Lactate Dehydrogenase (LDH) as a Potential Prognostic Factor for Relapsed/Refractory Aggressive B-Cell Lymphoma (R/R BCL) Patients Receiving CAR T Following Bridging Radiotherapy: Res
  

  Presenter: Monica Chelius, MD – University of Pennsylvania
• 8:10 AM – 8:15 AM ET

  Salvage Radiotherapy in LBCL After First Line Chemo-immunotherapy: Can We Avoid CAR-T Therapy?
  

  Presenter: Jessica Brady, MD, MB, ChB – Guy's and St. Thomas' NHS Foundation Trust
• 8:15 AM – 8:20 AM ET

  Patterns of Failure in Multiple Myeloma with Extramedullary Disease Following Anti-BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy
  

  Presenter: Justyn Nakashima, DO – Moffitt Cancer Center
• 8:20 AM – 8:25 AM ET

  Radiation Therapy as a Bridging Strategy in CAR-T Cell Therapy and the Impact of Tumor Control Status at CAR-T Cell Infusion
  

  Presenter: Takuya Shimizuguchi, MD – Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
• 8:25 AM – 8:30 AM ET

  Ultra-Hypofractionated Involved Site Radiation Therapy (ISRT) as Salvage or Bridging Therapy in Aggressive Non-Hodgkin Lymphomas
  

  Presenter: Tanooha Veeramachaneni, BS – UT Southwestern Medical School
• 8:30 AM – 8:35 AM ET

  Results of a Comprehensive Prospective Protocol of Radiotherapy Bridging and Consolidation for CAR T in Large B Cell Lymphoma (RESTART)
  

  Presenter: George Mikhaeel, MD, MBBS – Guy's Cancer Center
• 8:35 AM – 8:55 AM ET

  Questions & Answers
• 8:55 AM – 9:00 AM ET

  Closing